EGFR and lung cancer: Interestingly, EGFR-TKIs resistant cells upon treatment with dasatinib or transfection with small interfering RNAs (siRNAs) targeting SRC mRNA, significantly decreased AKT activation, cell survival and migration, indicating that Src inhibitors might overcome resistance to EGFR inhibitors in lung cancer cells [89].